Filing Flows › ANI Pharmaceuticals (ANIP) › Q1 2025
ANI Pharmaceuticals (ANIP) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 9, 2025
ANI Pharmaceuticals (ANIP) reported revenue of $197M for the first quarter 2025 (Q1 2025), +43% from a year earlier and +3% from the quarter before. Operating margin was 13.3%, net earnings $15.7M (8.0% of revenue).
ANI Pharmaceuticals, Q1 2025: revenue $197M (+43% year over year), operating margin 13.3%, net earnings $15.7M, operating cash flow $35.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $197M | +3% | +43% |
| Operating profit | $26.2M | — | +29% |
| Net earnings | $15.7M | — | -14% |
| Operating cash flow | $35.0M | +121% | +92% |
| Free cash flow | $32.5M | +141% | +138% |
What changed
Revenue was $197.1M in Q1 2025, up 43% year over year and up 3% from the previous quarter. Generic pharmaceutical products was the largest line at 50% of revenue. Generic pharmaceutical products added $28.5M year over year (up 41%), 48% of the total change. Royalties and other pharmaceutical services declined 5%.
Operating profit was $26.2M, a 13.3% margin (down 1.5 points year over year). Of the extra revenue versus a year earlier, 10% reached operating profit, below the 15% margin then. Total costs grew 46% against revenue growth of 43%. The fastest-growing cost line was SG&A (+59%). Net earnings were $15.7M, down 14% year over year. The effective tax rate was 21.5%.
Operating cash flow was $35.0M (up 92% year over year), 223% of net earnings. Non-cash charges added back $22.9M of depreciation and amortization and $8.9M of share-based compensation. Working capital and other items used $12.4M. Capital expenditures of $2.5M left free cash flow of $32.5M.
Questions
What was ANI Pharmaceuticals' revenue in the first quarter 2025?
ANI Pharmaceuticals (ANIP) reported revenue of $197M for the first quarter 2025 (Q1 2025), +43% from a year earlier and +3% from the quarter before.
Was ANI Pharmaceuticals profitable in the first quarter 2025?
Operating profit was $26.2M (13.3% of revenue) and net earnings $15.7M.